No Data
Express News | Guggenheim Reiterates Buy on Century Therapeuticsto Buy
4 Analysts Have This To Say About Century Therapeutics
H.C. Wainwright Maintains Century Therapeutics(IPSC.US) With Buy Rating, Maintains Target Price $5
Express News | HC Wainwright & Co. Reiterates Buy on Century Therapeutics, Maintains $5 Price Target
Express News | Century Therapeutics Inc: Caramel Trial With Century Is Intended to Commence in Mid-2025 Following Cta Approval
Express News | Century Therapeutics- Enters Investigator-Initiated Phase 1/2 Trial of Ipsc-Derived Ink Cell Therapy Cnty-101 in B-Cell Mediated Autoimmune Diseases